Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$3.56
-2.5%
$4.51
$2.30
$35.02
$15.17M1.1536,466 shs48,591 shs
Galecto, Inc. stock logo
GLTO
Galecto
$3.38
+3.7%
$3.43
$2.01
$15.13
$4.46M1.3532,552 shs10,032 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$0.85
+1.8%
$0.92
$0.79
$4.38
$16.53M0.79203,770 shs64,466 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$2.93
-1.7%
$3.20
$2.68
$6.17
$15.88M1.2436,327 shs5,978 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLineRx Ltd. stock logo
BLRX
BioLineRx
0.00%-8.01%-24.26%+15.21%-87.95%
Galecto, Inc. stock logo
GLTO
Galecto
0.00%+4.81%-4.14%+21.80%-74.00%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
0.00%-0.62%-4.08%-21.40%-73.00%
Lipocine Inc. stock logo
LPCN
Lipocine
0.00%-6.98%-10.40%+0.34%-33.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioLineRx Ltd. stock logo
BLRX
BioLineRx
2.201 of 5 stars
3.83.00.00.00.60.01.3
Galecto, Inc. stock logo
GLTO
Galecto
3.0316 of 5 stars
3.53.00.00.02.51.71.3
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
2.3219 of 5 stars
3.52.00.00.00.63.30.6
Lipocine Inc. stock logo
LPCN
Lipocine
2.6312 of 5 stars
3.55.00.00.01.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLineRx Ltd. stock logo
BLRX
BioLineRx
3.50
Strong Buy$26.00630.34% Upside
Galecto, Inc. stock logo
GLTO
Galecto
3.00
Buy$10.00195.86% Upside
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
3.00
Buy$4.00373.37% Upside
Lipocine Inc. stock logo
LPCN
Lipocine
3.00
Buy$9.00207.17% Upside

Current Analyst Ratings Breakdown

Latest GLTO, LPCN, LEXX, and BLRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
7/1/2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $5.00
6/27/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/17/2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/10/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
5/30/2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/29/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$8.00
5/28/2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$28.94M0.52N/AN/A$4.04 per share0.88
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/A$10.99 per shareN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$615.92K26.83N/AN/A$0.48 per share1.76
Lipocine Inc. stock logo
LPCN
Lipocine
$11.20M1.42N/AN/A$3.93 per share0.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$9.22M-$8.80N/AN/AN/A-15.21%-23.93%-6.80%8/14/2025 (Estimated)
Galecto, Inc. stock logo
GLTO
Galecto
-$21.44M-$13.13N/AN/AN/AN/A-115.70%-95.42%8/11/2025 (Estimated)
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/A
Lipocine Inc. stock logo
LPCN
Lipocine
$10K-$0.87N/AN/AN/A-23.59%-21.91%N/A

Latest GLTO, LPCN, LEXX, and BLRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$0.35N/AN/AN/A$0.66 millionN/A
8/14/2025Q2 2025
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.41N/AN/AN/A$0.23 millionN/A
8/5/2025Q2 2025
Galecto, Inc. stock logo
GLTO
Galecto
N/A-$2.60N/A-$2.60N/AN/A
8/5/2025Q2 2025
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.41-$0.41N/A-$0.41$1.00 million$0.62 million
7/14/2025Q3 2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million
5/27/2025Q1 2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLineRx Ltd. stock logo
BLRX
BioLineRx
N/AN/AN/AN/AN/A
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLineRx Ltd. stock logo
BLRX
BioLineRx
0.37
2.27
2.04
Galecto, Inc. stock logo
GLTO
Galecto
N/A
4.96
4.96
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/A
3.90
3.90
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
12.71
12.71

Institutional Ownership

CompanyInstitutional Ownership
BioLineRx Ltd. stock logo
BLRX
BioLineRx
1.56%
Galecto, Inc. stock logo
GLTO
Galecto
14.20%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
13.06%
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%

Insider Ownership

CompanyInsider Ownership
BioLineRx Ltd. stock logo
BLRX
BioLineRx
1.10%
Galecto, Inc. stock logo
GLTO
Galecto
10.80%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
26.40%
Lipocine Inc. stock logo
LPCN
Lipocine
6.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLineRx Ltd. stock logo
BLRX
BioLineRx
404.26 million4.22 millionOptionable
Galecto, Inc. stock logo
GLTO
Galecto
401.32 million1.18 millionOptionable
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
719.56 million14.40 millionNot Optionable
Lipocine Inc. stock logo
LPCN
Lipocine
105.42 million5.08 millionNo Data

Recent News About These Companies

Lipocine Begins Phase 3 Trial for LPCN 1154
Lipocine Reports Q1 2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLineRx stock logo

BioLineRx NASDAQ:BLRX

$3.56 -0.09 (-2.47%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$3.56 0.00 (0.00%)
As of 08/8/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Galecto stock logo

Galecto NASDAQ:GLTO

$3.38 +0.12 (+3.68%)
Closing price 08/8/2025 02:48 PM Eastern
Extended Trading
$3.40 +0.02 (+0.71%)
As of 08/8/2025 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Lexaria Bioscience stock logo

Lexaria Bioscience NASDAQ:LEXX

$0.84 +0.02 (+1.81%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$0.83 -0.01 (-1.30%)
As of 08/8/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Lipocine stock logo

Lipocine NASDAQ:LPCN

$2.93 -0.05 (-1.68%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$2.96 +0.02 (+0.85%)
As of 08/8/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.